

RNA Disease Diagnostics

RNA Disease Diagnostics, Inc.

Investor Presentation

Q3 2021

Disclaimer

Certain statements in this presentation may contain certain information that is "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws with respect to RNA Disease Diagnostics, Inc. ("RNADD" or the "Company"). Such statements include all statements other than statements of historical fact contained in this presentation, such as statements that relate to the Company's current expectations and views of future events. Often, but not always, forward-looking information can be identified by the use of words such as "may", "will", "expect", "anticipate", "predict", "aim", "estimate", "intend", "plan", "seek", "believe", "potential", "continue", "is/are likely to", "is/are projected to" or the negative of these terms, or other similar expressions, as well as future or conditional verbs such as "will", "should", "would", and "could" intended to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to our expectations regarding future clinical trials, expectations regarding regulatory approvals, expectations regarding the safety and efficacy of the Company's products, our expectations regarding commercializing our planned products and our ability to generate revenues and achieve profitability; our expectations regarding the impact of COVID-19 on our business, affairs, operations, financial condition, liquidity, availability of debt and equity capital, and results of operations; our expectations regarding the safety, efficacy and advantages of our products over our competitors and alternative diagnostic device options; our expectations regarding our products fulfilling unmet clinical needs and achieving market acceptance among customers; our expectations regarding reimbursement for our approved products from third-party payers; our ability to attract, develop and maintain relationships with other suppliers, manufacturers, distributors and strategic partners; our expectations regarding our pipeline of product development, including expanding the application of our intellectual property to additional product forms and additional indications; our expectations regarding current and future clinical trials, including the timing and results thereof; our expectations regarding receipt of regulatory approvals for our planned products and future product candidates; our mission and future growth plans; our ability to attract and retain personnel; our expectations regarding our competitive position for each of our planned products in the jurisdictions where we will seek approval; our ability to raise debt and equity capital to fund operations, product development, pursue regulatory approvals and commercialize our products when approved; and anticipated trends and challenges in our business and the markets in which we currently operate or may in the future operate.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The results, performance and achievements of the Company will be affected by, among other things, such as risks related to our limited operating history and history of net losses; risks relating to the extent and impact of COVID-19; risks related to our ability to commercialize our products when approved, including expanding our sales and marketing capabilities, increasing our manufacturing and distribution capacity, and achieving and maintaining market acceptance for our products; risks related to the regulation of our products, including in connection with obtaining regulatory approvals as well as post-marketing regulation; risks related to our successful completion of future clinical trials with respect to our products and future product candidates; risks related to managing growth, including in respect of obtaining additional funding and establishing and maintaining collaborative partnerships, to achieve our goals; risks related to competition that may impact market acceptance of our products and limit our growth; risks relating to fluctuating input prices and currency exchange rates; risks related to the reimbursement models in relevant jurisdictions that may not be advantageous; risks related to reliance on third parties, including our collaborative partners, manufacturers, distributors and suppliers; risks related to intellectual property, including license rights that are key to our business; and risks related to the loss of key personnel, and such other risks detailed from time to time. The Company's forward-looking statements are made only as of the date of this presentation and, except as required by applicable law, RNADD disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, unless required by applicable law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, and because of the above-noted risks, uncertainties and assumptions, readers should not place undue reliance on forward-looking statements due to the inherent uncertainty in them.

Executive Summary

Executive Summary: Company Overview

Overview

- RNA Disease Diagnostics, Inc ("RNADD" or the "Company") was formed to commercialize an innovative molecular diagnostic platform that will contribute to the prevention of infectious disease transmission and better health for the citizens of the world
- The Company has an exclusive global license to the IP and diagnostic platform, which was created at the University of Maryland, Baltimore
- RNADD's proprietary Antisense Molecular Diagnostic Platform ("*Antisense*") will be positioned to compete in the rapidly growing Point of Care ("POC") and Home Use Test ("HUT") infectious and other disease testing markets, with near term capabilities in lab testing environments
- A crucial shortcoming of the healthcare system has been the inability to conveniently, rapidly and accurately diagnose infectious disease at POC or at home leading to heightened transmission as the world has been witnessing for over a year with the COVID-19 pandemic
  - The gold standard RT-PCR test is expensive, inconvenient, has a slow turnaround time and requires expensive hardware and trained technicians to oversee.
  - Other diagnostics such as Antigen tests suffer from lower accuracy, sensitivity and specificity (only 50% - 90%), and are generally least effective in detecting asymptomatic positive infections and infection at an early stage – the cases that are most likely to cause mass virus spreading
  - **The RNADD *Antisense* COVID-19 test kit delivers gold standard accuracy consistent with a RT-PCR test and is as quick and convenient as an Antigen test**

Major Covid-19 Testing Technologies

	RT-PCR	*RNADD Antisense*	Antigen
What Is Detected	Molecular RNA	**Molecular RNA**	Viral Protein
Speed Of Test	1-4 days	**<5 minutes**	<45 minutes
Detectability (from symptoms)	2 days	**2 days**	~5 days
Diagnostic Site	Laboratory	**LAB, POC & HUT**	POC & HUT
Sensitivity (Positive Result)	~98%	**96.7%**	~50%-90%
Specificity (Negative Result)	~98%	**100%**	~95%
Major Benefit	Gold Standard	**Gold Standard + Quick Speed**	Speed
Major Challenge	Capacity Constraint / Turnaround Time	**Needs Regulatory Approval**	Low Sensitivity
Conclusion		**Accuracy of PCR & Speed of Antigen**	

Additional Representative Testing Applications

Pandemics	Respiratory	STDs	Women's Health
▪ COVID-19	▪ Influenza	▪ Herpes	▪ HPV
▪ SARS	▪ Strep	▪ Gonorrhea	▪ UTI
▪ MERS	▪ Tonsillitis	▪ Syphilis	▪ Bacterial Vaginosis
▪ Ebola	▪ Pharyngitis	▪ Chlamydia	▪ Trichomonas
▪ Bird Flu	▪ Adenovirus		

RNA Disease Diagnostics

Executive Summary: Company Highlights

1 Market Leading Product Offering	■ The RNADD Molecular *Antisense* test kit delivers gold standard accuracy consistent of a RT-PCR test and is as quick and convenient as an Antigen test ■ The Company's first products will be a laboratory-approved test followed by a CLIA-waived point-of-care (POC), and home-use test (HUT) ■ POC and HUT molecular diagnostic test kit that accurately, quickly and affordably detects COVID-19 in less than 5 minutes ■ Clinical trials have shown 98.4% accuracy, 96.7% sensitivity, and 100.0 % specificity
2 Accelerated Go-to-Market Opportunity	■ The regular Medical Diagnostic Approval Process in the US is generally achieved through a FDA 510(k) submission. Timing to approval post-submission is, on average, ~6 months and clinical test equivalency is required on hundreds of patients ■ Due to the COVID-19 global health emergency, the FDA and other global regulatory bodies have provided an accelerated approval pathway. In the US, this accelerated approval is designated as an Emergency Use Authorization ("EUA") and timing to approval post-submission is shortened to weeks from months. Clinical testing equivalency is required on ~30 positive and ~30 negative patient samples
3 Multi – Channel Presence	■ RNADD diagnostic testing will have use-case capabilities across multiple critical end-market channels, including laboratory testing, POC and HUT ■ Point-of-care and home-use testing are expected to be CLIA waived for general use
4 Intellectual Property Protection	■ RNADD owns the global IP license to the proprietary technology including, antisense oligonucleotides, dual gene targeting, gold nanotechnology, electrochemical biosensor, and colorimetric, naked eye detection ■ Six provisional patents have been filed for *Antisense* COVID-19 & other molecular disease testing. Provisional patent filings are being converted to national and global patent applications during 2021

Executive Summary: Company Highlights (cont.)

5 Strong Unit Economics and Unique Revenue Profile	▪ The Company is planning to produce and sell lab-based and POC test kits at costs equal to or below incumbent players. Current hardware costs estimated to be a one-time customer expense of a few hundred dollars. Consumable component of the test is expected to support market place competitive pricing ▪ The Company forecasts being able to generate revenue in the near-term by going to market with COVID-19 testing while continuing to develop and commercialize its long-term diagnostic platform. By contrast, many diagnostic platforms require underwriting minimal revenue generation for as many as 24 months
6 Attractive Industry Dynamics	▪ The POC testing market alone is expected to reach $50 billion by 2026 with RNADD having a unique capability to provide an accurate POC test (RT-PCR equivalent) in under 5 minutes with affordable cost hardware and consumables ▪ RNADD's target POC market segments of respiratory, STDs, and women's health naturally lend themselves to a rapid, affordable POC or HUT and we expect these to be the fastest growing segments of the overall diagnostic testing market ▪ In the near term, COVID-19 testing allows the Company to address a large, pervasive global health issue. During calendar year 2020, in excess of 1 billion COVID-19 tests were performed globally, for an estimated value of $50 billion. U.S. average daily testing volume exceeded 1.8 million in 2020; ongoing COVID-19 testing will be critical to re-open the economy and keep it open over the next 12 – 24 months
7 Exceptional Leadership Team	▪ RNADD has assembled an exceptional leadership team, who collectively have many decades of industry experience spanning senior leadership roles in publicly traded health sciences and pharmaceutical companies, academic and applied research in the diagnostics field, and biotechnology investing ▪ Furthermore, the Company's Board of Directors and Advisory Board collectively consist of executives and senior leaders with substantial experience in the functional areas of corporate governance, capital markets, accounting & finance, law, and the public sector

Company Overview

Company Overview

RNA Disease Diagnostics is developing and commercializing a best-in-class global molecular diagnostic platform contributing to the prevention of infectious disease transmission and better health for the citizens of the world

Mission

- Contribute to the early detection and prevention of infectious disease transmission
- Leverage our proprietary *Antisense* RNA molecular diagnostic platform across multiple growing disease diagnostic categories
- Create highly accurate, quick, affordable, easy to administer and minimally invasive disease diagnostic testing kits for use at point of care and in home

Platform

- The Company utilizes a patented platform technology applied to develop and manufacture proprietary molecular disease diagnostic testing kits
- The Company has an exclusive global license to the IP and diagnostic platform created at the University of Maryland, Baltimore
- RNADD's proprietary *Antisense* Molecular Diagnostic Platform will be positioned to compete in the rapidly growing Laboratory, Point of Care and Home Use Test disease testing markets

Execution

- *Antisense* molecular diagnostic tests for Lab, Point of Care (POC) and Home Use Test (HUT) for Emerging Infectious Diseases, Respiratory Infections, Sexually Transmitted Diseases, and Women's Health Infections
- **Phase I:** First product is the Company's molecular *Antisense* COVID-19 Laboratory Approved assay
- **Phase II:** Develop and commercial RNADD's CLIA waived POC and HUT testing for COVID-19 and development of tests for other Respiratory, Sexually Transmitted and Women's Health diseases

Product Highlights

	RT-PCR	RNA Disease Diagnostics RNADD Antisense	Antigen
Type of Test	Molecular RNA	**Molecular RNA**	Protein
Sensitivity (Positive Result)	~98%	**96.7%**	~50%-90%
Specificity (Negative Result)	~98%	**100%**	~95%
Speed of Test	1-4 days	**<5 minutes**	<45 minutes
Detectability (from date of symptom)	2 days	**2 days**	~5 days
Diagnostic Site	Laboratory	**Lab, Point of Care, Home Use**	Point of Care

RNA Disease Diagnostics

Multi-Channel Product Offerings

- The Company will compete across channels and offer diagnostic testing with applications capable for use in laboratories, at point of care locations, and in-home
  - POC and HUTs will be CLIA waived and are intended to offer high ease-of-use for those administering the test
  - Decreasing barriers to test taking enables incremental testing frequency, allowing authorities and communities to have optimal data regarding viral cases
- RNADD's testing will also be able to conduct both single patient tests and multiple patient tests simultaneously
  - Single patient testing will be done on-site in clinics and physicians offices close to where patient's live, including stand alone physician offices, pharmacy clinics, long-term care facilities, nursing homes, etc., as well as in patient's homes
  - Multiple rapid flow individual testing will be done on-site and in locations where large groups congregate, including offices, government buildings, manufacturing plants, shopping malls, airports, sporting venues, etc.

Channel Summary

Point of Care (POC)

- Point-of-care testing occurs at local and potentially high-traffic locations such as airports, restaurants, and stadiums
- Tests are taken at these locations with point-of-care diagnostic platforms such as RNADD's *Antisense* COVID-19 test. Results are then received within 5 minutes

Laboratory Testing

- Viral testing today is largely performed in centralized laboratories; this however is inefficient due to the elapsed testing time and the time it takes to ship samples to and from test sites
- Testing works well in labs and may be able to increase lab throughput given the *Antisense* 5 minute, low turnaround times

Home Use Test (HUT)

- Home-use testing will further allow individuals to take control of their ability to get tested and receive timely results from the comfort of their home
- RNADD *Antisense* test kits are expected to be CLIA-waived, which will validate the ease of use for home-use testing that the Company's platform offers

Intellectual Property

RNADD owns the global exclusive IP created at the University of Maryland, Baltimore to proprietary technology including, antisense oligonucleotides, dual gene targeting, gold nanotechnology, electrochemical biosensor, and colorimetric, naked eye detection

Intellectual Property Summary

- Six provisional patents have been filed for *Antisense* COVID-19 & other molecular disease testing:
  - Antisense oligonucleotides (similar to a formulation patent)
  - Testing methodologies and protocols (similar to process patents)
  - Expansion of IP to cover testing for other infectious diseases (similar to a use patent)
  - Electrochemical biosensor technology for rapid infection diagnosis (similar to a device patent)
  - Conjugation of oligonucleotides with redox agent (unique and proprietary process)
- Provisional patent filings are being converted to national and global patent applications during 2021
- Discoveries published in highly regarded peer-reviewed scientific journals including Nature Protocols and ACS Nano[(1)]



1) For further review, see the following peer-reviewed journal articles: (i) https://pubs.acs.org/doi/10.1021/acsnano.0c03822, (ii) https://pubs.acs.org/doi/10.1021/acsnano.0c06392 and (iii) https://www.nature.com/articles/s41596-021-00546-w

Commercialization Phases

RNADD plans to roll out its testing platform in two phases: (i) In the near-term, COVID-19 testing and (ii) over the next few years, company anticipates 510(k) approvals to commercialize test kits for other, respiratory viruses, women's health and sexually transmitted diseases

	Applications	Commentary
Phase I	**COVID-19 Testing**	▪ The COVID-19 testing market exponentially grew throughout 2020. With ongoing concerns around vaccine dissemination, threat of incremental variants, and a desire to re-open the global economy, testing for COVID-19 remains a likely opportunity for the next 12 – 24 months ▪ The Company is well-positioned to commercialize its *Antisense* testing kit for COVID-19 in 2021 and take advantage of the $50 billion global COVID-19 market opportunity
Phase II	**Pandemics**	▪ For future pandemics, governments are likely to stockpile resources to mitigate broad-based impact of testing supply shortage as experienced during the COVID-19 pandemic. ▪ Applications for pandemics include COVID-19, SARS, MERS, Ebola, Bird Flu, and importantly, any other virus that are identified and have the potential for rapid spread, virulence, and global impact in the future
	Respiratory Viruses	▪ The Company's testing kit will also be developed to test for respiratory viruses such as Influenza, Strep, Tonsillitis, Pharyngitis, and Adenovirus, STDs such as Herpes, Gonorrhea, Syphilis, Chlamydia, and women's health viruses such as HPV, UTI, Bacterial Vaginosis, and Trichomonas
	Sexually Transmitted Diseases	▪ The Company's broader applications POC markets represented a testing opportunity of $29 billion in 2020 and is forecasted to reach $50 billion globally by 2026
	Women's Health	▪ While the Company capitalizes on the near term COVID-19 testing opportunity, it will simultaneously be conducting R&D, seeking approvals and commercializing its diagnostic testing platform and test kits for these broader applications and market opportunities

Company Leadership

Executive Team

Allan Oberman Executive Chairman & Co-Founder	▪ A 30 year C-Suite healthcare executive Mr. Oberman has served as CEO of Concordia International Corp., Sagent Pharmaceuticals Inc., Teva Pharmaceuticals Americas, Teva Pharmaceuticals International, and Novopharm Ltd. ▪ Mr. Oberman serves on the Board of Directors of Dr. Reddy's Laboratories Ltd.
John W. Erickson, Jr. President	▪ Mr. Erickson has more than thirty years of C-Suite and executive leadership experience in life science and diagnostics with Johnson & Johnson, Abbott Labs, ITC/Nexus Diagnostics and RapidBio systems ▪ He has been responsible for the development, commercialization and management of over 36 products with cumulative revenues in excess of $4 billion
Allen Chepuri Chief Operating Officer & Co-Founder	▪ Mr. Chepuri brings twenty years of financial industry experience and was a former hedge fund manager ▪ He is co-founder and Managing Partner of LIFE Technology Ventures LLC, a healthcare holding company. Mr. Chepuri specializes in deep value technology and biotechnology investments with long-term potential and minimal risk
Josh Blacher Chief Financial Officer	▪ Mr. Blacher has over 20 years of financial experience as the former CFO of three NASDAQ publicly traded healthcare companies ▪ He started his career in investment banking working with Lehman Brothers, Deutsche Bank, and Cowen Inc., and has worked on IPO's, follow-on offerings, M&A transactions, with public and private companies
Dr. Dipanjan Pan Chief Scientific Advisor & Inventor	▪ Dr. Pan is a tenured Full Professor in Diagnostic Radiology & Nuclear Medicine, Pediatrics and Chemical, Biochemical and Environmental Engineering at University of Maryland Baltimore School of Medicine and University of Maryland Baltimore County and an expert in nanomedicine, molecular imaging, and drug delivery

Board of Directors

Allan Oberman	▪ A 30 year C-Suite healthcare executive Mr. Oberman has served as CEO of Concordia International Corp., Sagent Pharmaceuticals Inc., Teva Pharmaceuticals Americas, Teva Pharmaceuticals International, and Novopharm Ltd. ▪ Mr. Oberman serves on the Board of Directors of Dr. Reddy's Laboratories Ltd.
Allen Chepuri	▪ Mr. Chepuri brings twenty years of financial industry experience and was a former hedge fund manager ▪ He is co-founder and Managing Partner of LIFE Technology Ventures LLC, a healthcare holding company. Mr. Chepuri specializes in deep value technology and biotechnology investments with long-term potential and minimal risk
Richard W. Fisher	▪ Richard W. Fisher is the former President and Chief Executive Officer of the Federal Reserve Bank of Dallas and also served as Deputy U.S. Trade Representative with the rank of Ambassador ▪ He is an Honorary Fellow of Hertford College, Oxford University, and a Fellow of the American Academy of Arts and Sciences. Mr. Fisher serves or has served on the Boards of Directors of AT&T, PepsiCo and Tenet Healthcare
Patrice Allibert	▪ Patrice Allibert, a PhD in molecular biology and microbiology has more than 35 years of experience in four major biotechnology companies. He is the Former CEO of GenePOC, a company acquired by Meridian BioSciences ▪ Mr. Allibert was Vice President R&D and Strategic Innovation for Molecular Infectious Diseases at Becton Dickinson where he developed and launched multiple diagnostic tests for hospital acquired infections
Richard Ganz	▪ Richard Ganz is a 40 year life sciences executive with pharmaceutical and medical device experience at Abbott Laboratories, Baxter Healthcare, and served as CEO of OmniSonics Medical Technologies. ▪ He is Executive Chairman of Sentien Biotechnologies, and a member of the Board of Kalocyte Inc.
Jordan Kupinsky	▪ Jordan Kupinsky has more than 20 years of experience in merchant banking, investment banking and law ▪ He is currently Managing Partner of Windsor Private Capital and has served on several public and private company boards including Concordia International, Atlas Financial Holdings, Xceed Mortgage Corporation, and Perk Inc.
John Manley	▪ The Honorable John Manley is one of the most respected business leaders in Canada. For over a decade, he served in the Federal Government as Canada's Deputy Prime Minister, Minister of Foreign Affairs, Finance Minister, and Industry Minister. More recently, he was President and CEO of the Business Council of Canada. ▪ Mr. Manley is Chair of the Board of CAE Inc., former Chair of CIBC, and a member of the Board of TELUS

Board of Advisors

Alec Burger	▪ Alec Burger is the Former President and CEO of GE Capital, and Chairman of GE Capital Aviation Services (GECAS). Alec was responsible for financial operations in 34 countries and ~$150B in assets ▪ He has served as Vice Chairman of the Connecticut Chapter of the National Multiple Sclerosis Society and a Board Member of the Stepping Stones Museum for Children in Norwalk, CT
Charles R. Black	▪ Charles R. Black is Chairman of Prime Policy Group, and is widely recognized as a leading public affairs professional ▪ Serving as a principal legislative and public affairs advisor to several Fortune 500 companies and trade associations, he also leads Prime Policy Group client teams in several public policy disciplines
Sunir Chandaria	▪ Sunir Chandaria serves as President of Chandaria Family Holdings and manages a portfolio of public and private investments. Sunir was formerly President of LePage's, a portfolio company that is a leader in office supplies distribution to major retailers around the globe ▪ Member of the Institute of Corporate Directors (ICD) having served on Boards of many private and public organizations
Nicholas Howard	▪ Nicholas Howard is co-Founder of LIFE Technology Ventures LLC and has an MA in Law from Oxford University and London Law School. A trained attorney with almost 40 years of finance experience at Barclays, Lehman and HSBC, working in New York, London, Toronto, Tokyo and Dallas ▪ Currently CO-CEO of Queen Elizabeth II Memorial Garden, New York working to support the Navy SEAL Foundation
Cheryl Reicin	▪ Cheryl Reicin is the practice leader of Torys' Life Science Group, a cross-border group in the US and Canada ▪ She represents the whole spectrum of biotech, medical device and health technology companies, from start-ups to large public companies ▪ She has been named WXN's Canada's Top 100 Most Powerful Women four times and is inducted into its Hall of Fame
Bruce Rothney	▪ Bruce Rothney is the Chairman, CEO and Country Head for Barclays Canada. Mr. Rothney has 30 years of leadership, general management, and transaction experience in investment banking and financial services ▪ He is Vice Chair of the Board of Canadian Cancer Society, a Fellow of the Duke of Edinburgh Awards, and a board member of Rogers Bank

Design & Applications

Antisense Planned Laboratory Approved EUA COVID-19 Test

Antisense Covid-19 Testing Unique Features

- No RNA isolation step required
- No heat amplification necessary
- No need for expensive lab centrifuge
- No complex expensive hardware equipment required
- Quicker to administer and read result than an Antigen test
- Sample to results in less than 5 minutes
- Lowest LOD (Level Of Detection) – 2.85 copies/µL

Antisense Proprietary Process

Detection
Nanotechnology
Antisense
Oligonucleotides
Electrochemical
Detection Process

Extraction
Reagent &
Process

RNA Disease Diagnostics

Antisense Future POC Test Kit and Process Flow

Step 1

- Open packaging, which will contain a swab and cassette



Step 2

- Scan QR Code on phone app

Step 3

- Provide personal identification details such as name and phone number to database through a unique link

Step 4

- Collect anterior nares samples



Step 5

- Insert swab and close cap

Step 6

- For ***single patient testing,*** connect to reader and run test

- For ***multiple patient testing,*** insert each cartridge into the multi bay instrument and run test

Step 7

- Results upload to HIPAA Compliant Cloud and delivered to where required (SMS, Email, EMR, Local Health Bureau etc.)

RNA Disease Diagnostics

Case Study: COVID-19 High-Traffic Venue Testing

Initial Deployment Tests for COVID-19 via POC Kit

- The *Antisense* POC test kit will be deployed at high-traffic venues:

Airports

Office Buildings

Shopping Malls

Manufacturing Sites

Hospitals

Nursing / Long Term Care Homes

Illustrative Use Case – Airport /Office / Workplace

1. Arrive early before flight, event or workday begins

2. Test administered

3. Receive Result <5 minutes

4. Negative Result = Entry
   Positive Result = Refusal

Summary

- Quick and accurate testing at high traffic venues will contribute to returning the economy to its pre-COVID-19 state
- Use of *Antisense* Molecular COVID-19 POC testing has numerous benefits:
  - **Immediate**: Eliminates long delay between taking a RT-PCR test and receiving the result
  - **Convenient:** Appointment scheduling is not necessary; testing is done on-site
  - **Accurate:** >98% accuracy provides confidence to return to a normalized way of life
  - **Compliant:** Those who test positive can immediately self isolate and/or seek medical assistance

Antisense Future Home Use Test

HUT's that allow individuals to test themselves for infectious disease are a critical component in early detection and controlling spread. For COVID-19 it is even more important to enable the opening of the economy while helping prevent the spread of new and potentially more virulent variants

- RNADD's *Antisense* HUT will provide high accuracy and quick administration similar to the Company's POC diagnostic test
- RNADD's *COVID-19 HUT* is targeted for development in 2022 and is expected to be CLIA waived for general population use

Relevant Expert Commentary

"We need to flood the system with testing so you can get a feel for the penetration of this community spread, which is asymptomatic spread…The thing I would be pushing for is something that's a home …that you can do yourself…where we don't even require a prescription…If you had a test that you could do at home, yourself, point of care, sensitive and specific you could eliminate a lot of that [who is infected and who's not]."

– Dr. Anthony Fauci, November 19, 2020

"A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, but all of that needs to be confirmed. And again, the variants will play a key role"

– Albert Boula, Pfizer CEO, April 1, 2021

RNA Disease Diagnostics

Industry and Market Overview

RNADD Targeted POC and HUT Markets

- The Company is focused on the below key markets as a result of the following:
  - In response to COVID-19, governments around the world will be allocating incremental budget to have the tools (test kits, PPE etc.) stockpiled and in-place to mitigate the likelihood that the next potential pandemic will result in the devastating human and economic impact that has resulted from COVID-19
  - The identified Respiratory, STD and Women's Health markets will disproportionately benefit from the movement from central laboratory to Point-of-Care and Home-Use Testing following the movement of primary physicians from medical buildings into the community and with the growth of tele-health



Total Addressable Testing Market

- RNADD's target addressable market was valued at approximately US$149.0 billion in 2020 and is expected to reach US$242.3 billion by 2027, registering a CAGR of 7.2%
  - The market is expected to grow due to the increasing incidence of infectious and chronic diseases and the increasing adoption of automation
- The global point-of-care diagnostics / testing market size was US$29.5 billion in 2020 and is projected to reach US$50.6 billion by 2027, exhibiting a CAGR of 11.4%

RNA Disease Diagnostic End Markets



RNA Disease Diagnostics

Source: Meticulous Research, Research Dive, Allied Market Research, Verified Market Research, Markets and Markets, Market Data Forecast, Reports and Data

COVID-19 Testing Market

- The COVID-19 testing market saw exponential growth throughout 2020 and 2021
- It is estimated that the COVID-19 testing market represents an annualized revenue opportunity in excess $50 billion globally
- Several global healthcare leaders have indicated a need for ongoing testing for the foreseeable future, based on potential new variants, time needed to reach herd immunity, and unknown duration of vaccine protection

North America & EU-5 Global Testing Share



G20 Cumulative COVID-19 Testing Volume



RNA Disease Diagnostics

Source: Our World in Data

Concluding Summary

RNA Disease Diagnostics - In Summary

Growing Market Application

Pandemic
MERS - SARS - Ebola - Covid-19

Respiratory
Flu - Strep - Pharyngitis - Adenovirus

STD
Herpes - Gonorrhea - Syphilis - Chlamydia

Women's Health
HPV - UTI - Bacterial Vaginosis

Differentiated Diagnostic Platform

Single:
Point of Care
& Home Use

Multiple:
Point of Care

Proprietary Antisense Covid-19 Process

Detection
Nanotechnology
Antisense
Oligonucleotides

Extraction
Reagent
and
Process

Highly Accurate AND Fast

Antisense Covid-19 Test:

Has Accuracy of RT-PCR
>98%

With Speed of Antigen
<5 Mins

Easy to Administer and Read

Anterior
Nasal
Swab

Electronic
Read

Reopens the Economy

RNA Disease Diagnostics